Shares of Incyte tumbled 30 percent in early trading today after the company acknowledged that the FDA has asked it to mount a new mid-stage trial of its HIV drug Reverset. The agency wants more data on the drug's safety and efficacy in treating HIV patients who had already received other treatments. That will delay two Phase III trials and push back any potential market launch.
- read this story from MarketWatch for more